Dana Faratian

Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.

DCIS and aromatase inhibitors.

Dynamic computational modeling in the search for better breast cancer drug therapy.

Diesel exhaust inhalation increases thrombus formation in man.

Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma.

Pleural Wegener's granulomatosis: a rare presentation.

PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.

Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing service.

Systems pathology--taking molecular pathology into a new dimension.

Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab.

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.

Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.

How can systems pathology help us personalize cancer therapy?

The importance of growth factors and steroid hormones in ovarian cancer.

Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: the TEAM Trial Experience.

COX2 表达式在预后和预测内分泌治疗的早期乳腺癌患者。

Pertuzumab for the treatment of ovarian cancer.

Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer.

Cancer systems biology.

Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.

Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition.

Systems pathology.

Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy.

Higher incidence of isolated brain metastases in ovarian cancer patients with previous early breast cancer.

What can molecular pathology contribute to the management of renal cell carcinoma?

Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.

Two possible mechanisms of epithelial to mesenchymal transition in invasive ductal breast cancer.

Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients.

Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy.

Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.

GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines.

Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network.

Validation of activated caspase-3 antibody staining as a marker of apoptosis in breast cancer.

The use of automated quantitative analysis to evaluate epithelial-to-mesenchymal transition associated proteins in clear cell renal cell carcinoma.

HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis.

Diversity of matriptase expression level and function in breast cancer.

Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer.

Transcript and protein profiling identify signaling, growth arrest, apoptosis and NFκB-survival signatures following GnRH receptor activation.